Samsung Bioepis says Eli Lilly visit was a courtesy meeting
Related tags: Samsung, Bioepis, Lilly, Biosimilars, Manufacturing
Samsung Bioepis has denied it is about to do a biosimilars deal with Eli Lilly after the US drug firm visited its headquarters in Korea.
Eli Lilly’s visit to Bioepis and its sister unit Samsung Biologics on Wednesday was reported in the Korean press , prompting speculation the firms were about to make a deal.
The Korea Herald suggested Lilly’s Lantus biosimilar Basaglar (insulin glargine injection) – which is due to be launched in the US in December – would be the focus.
However, Samsung has denied that any such deal was discussed telling us the meeting with Lilly was a courtesy call.
"We would like to clarify that this was a courtesy meeting that did not involve any discussions about potential cooperation or partnerships."
Merck & Co deal
Bioepis already has an insulin biosimilar deal with a US drug manufacturer.
In 2012, it teamed up with Merck & Co to develop and commercialise biosimilar products.
The biosimilars include versions of J&J’s Remicade (infliximab), AbbVie’s Humira (adalimumab) and Roche’s Herceptin (trastuzumab) and Brenzys, a version of Amgen’s arthritis TNF inhibitor Enbrel (etanercept) that was approved in Korea in September .
The fifth is a version of Sanofi’s insulin glargine product Lantus.
Samsung Bioepis is currently considering an initial public offering (IPO) .